Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications

Bibliography

• Muggia F. Introduction: why a supplement on taxanes? Anticancer Drugs 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. Clin Cancer Res 2013;19:17-4570-7
   Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter A, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:final results of a phase III trial. J Clin Oncol 2012;30:2055-62
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011;122(2):226-32
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 2008;8(4):352-6
   PubMed Web of Science ®Google Scholar
• Rugo HS, Barry WT, Moren-Aspitia A, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel, compared to weekly nanoparticle albumin bound nab-paclitaxel, or ixabepilone with or without bevacizumab as first line therapy for locally recurrent or metastatic breast cancer [abstract]. J Clin Oncol 2012;30(Suppl):abstract CRA1002
   Google Scholar
• Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet Oncol 2013;14(10):1020-6
   PubMed Web of Science ®Google Scholar
• Landrum LM, Gold MA, Moore KN, et al. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 2008;108(2):342-7
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 2012;12:313-21
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• Betticher DC, Delmore G, Breitenstein U, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 2013;21(9):2565-73
   PubMed Web of Science ®Google Scholar
• Miller D, Fillaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771-3
   Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7
   PubMed Web of Science ®Google Scholar
• Posner MR. Taxanes in cancer of head and neck. Anticancer Drugs 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Balar AV. The impact of taxanes on the management of genitourinary cancers. Anticancer Drugs 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116(16):3969-77
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Abonour R, Kesler KA. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide for patients with relapsed primary mediastinal nonseminomatous germ cell tumors: benefit from chemotherapy, surgery, or both? J Clin Oncol 2010;28(35):e739
   PubMed Web of Science ®Google Scholar
• Jalal S, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 2010;5(12):2008-11
   PubMed Web of Science ®Google Scholar
• Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol 2013;71(1):183-91
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Perez DJ, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer 2013;119(3):586-92
   PubMed Web of Science ®Google Scholar